Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation.
Santosh Gautam, Laura Morrison, Philippe Thompson-Leduc et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III comparative study evaluated the economic impact of daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma patients. At 60 months, DVRd resulted in $652,113 lower costs per patient achieving minimal residual disease (MRD) negativity compared to VRd, with 60.9% of patients achieving MRD negativity in the DVRd group versus 39.4% in the VRd group.
Key findings
- DVRd resulted in $652,113 lower costs per patient negative for MRD compared to VRd.
- 60.9% of patients achieved MRD negativity with DVRd versus 39.4% with VRd.
- Cost per patient achieving sustained MRD negativity was $1,964,539 lower with DVRd than VRd.
- DVRd had a lower 2L treatment cost of $186,371 compared to $958,840 for VRd.
Why it matters
Understanding the cost-effectiveness of treatment options is crucial for healthcare providers, especially in managing resources for patients with multiple myeloma. The findings suggest that DVRd not only offers superior clinical outcomes but also significant cost savings.